Non-invasive localization Target healthcare providers and labs focusing on liver disease and metabolic conditions who would benefit from AI-driven non-invasive diagnostics such as LIVERFASt and HealthFACTR to improve screening for NAFLD, NASH, fatty liver disease, and related cardiovascular risk.

Strategic partnerships Leverage ongoing and past partnerships (Stone Diagnostics, American Liver Foundation) to co-sell or co-market non-invasive diagnostic tools, expanding reach into primary care, hepatology, and specialty clinics while leveraging their networks for referrals and validation.

AI driven value Position solutions as action-oriented, risk-prediction tools that help clinicians triage, monitor progression, and tailor interventions for liver disease, cardiovascular risk, stroke, and diabetes, addressing a market need for cost-effective, non-invasive diagnostics.

Funding momentum Highlight recent funding milestones and AI-driven diagnostics leadership to attract strategic investors and customers seeking validated technology, regulatory-ready solutions, and scalable deployments in hospital networks.

Mid-market focus Target mid-sized hospitals and health systems with 11-50 employees in the health tech space, emphasizing accessible implementation, existing tech stack compatibility, and rapid time-to-value for liver and metabolic disease screening.